Supplementary data: Overcoming negative predictions of MicroRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

FOLFIRINOX
is superior to gemcitabine in patients with pancreatic cancer, but this
regimen is associated with toxicity and biomarkers for response are
warranted. MicroRNAs can mediate drug resistance and could provide predictive
information. Altered expressions of several microRNAs including miR-21-5p,
miR-10b-5p, and miR-34a-5p have been previously linked to a worse response to
gemcitabine. We investigated the influence of expression levels in tumor
tissue of those three microRNAs on outcome to FOLFIRINOX. Twenty-nine
patients with sufficient formalin-fixed paraffin-embedded tumor tissue were
identified. There was no significant association between high and low
expression groups for these three microRNA. We conclude that polychemotherapy
combination can overcome intrinsic negative prognostic factors.